Genmab — Juni 2014
-
kunne godt bruge lidt nyt fra teknologifronten snart
-
men herudover kan phase III data fra det 4 Arzerra studier jo også komme anytime nu
-
Ja lad os håbe, at solen snart står op over Genmab. Er det FF 1:08 inde i videoen? https://www.youtube.com/watch?v=JJ91ikAhJ5Q
-
så kom der lidt tempo på anomyus
-
Skønt. Vi har det altid godt når Carsten går igang
-
Interessant OFA ADC eksperiment: http://link.springer.com/article/10.1007/s10637-013-9995-y#
-
hvem ejer den ADC teknologi som er brugt ?
-
Genmab ligner en med momentum igen efter både Carnegie og Anomyus er med
-
Kan se at den samme ADC har været brugt med rituxan for 10 år siden: http://clincancerres.aacrjournals.org/content/10/23/7842.long
-
Rettelse...Det er ikke direkte seattle teknologi, det lader til at komme fra Concortis Biosystems (http://www.concortis.com) som er medforfatter på artiklen.
-
Sorrento Therapeutics acquires Concortis Biosystems
Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.
News-Medical (www.news-medical.net)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind